(NASDAQ: ABCL) Abcellera Biologics's forecast annual revenue growth rate of -20.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Abcellera Biologics's revenue in 2026 is $79,207,000.On average, 11 Wall Street analysts forecast ABCL's revenue for 2026 to be $9,969,895,831, with the lowest ABCL revenue forecast at $7,725,692,068, and the highest ABCL revenue forecast at $12,396,103,328. On average, 10 Wall Street analysts forecast ABCL's revenue for 2027 to be $10,702,186,023, with the lowest ABCL revenue forecast at $8,142,529,479, and the highest ABCL revenue forecast at $13,672,267,095.
In 2028, ABCL is forecast to generate $12,597,040,337 in revenue, with the lowest revenue forecast at $8,142,529,479 and the highest revenue forecast at $15,666,673,787.